Suven Life Sciences, a biopharmaceutical company, secured product patent in Mexico and Singapore. The product patent corresponds to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases. These patents are valid through 2029.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of eighteen granted patents from Mexico and twenty granted patents from Singapore. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally,'' said Venkat Jasti, CEO of Suven.
Shares of the comapny are trading at Rs 316.85, up Rs 5.9, or 1.90% at the Bombay Stock Exchange (BSE) on Friday at 10:26 a.m.